Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Manu

Showing results (51-60 of 93) with videos related to

Pageof 10
Sort By:
Expert Review of Clinical Pharmacology|January 19, 2018
The pharmacological management of metabolic syndromeJulie Rask Larsen, Lorena Dima, Christoph U Correll, et al.
Expert Opinion on Drug Metabolism & Toxicology|June 6, 2022
Drug-drug interactions involving antipsychotics and antihypertensivesCatalin Adrian Buzea, Lorena Dima, Christoph U Correll, et al.
American Journal of Therapeutics|September 1, 2021
Pharmacological Management of Peptic Ulcer: A Century of Expert Opinions in Cecil Textbook of MedicinePeter Manu, Liliana M Rogozea, Vlaicu Sandor, et al.
Expert Opinion on Drug Metabolism & Toxicology|November 12, 2022
Drug-drug interactions involving combinations of antipsychotic agents with antidiabetic, lipid-lowering, and weight loss drugsCatalin Adrian Buzea, Peter Manu, Lorena Dima, et al.
American Journal of Therapeutics|September 27, 2012
Acanthosis nigricans during treatment with aripiprazolePeter Manu, Zainab Al-Dhaher, Navin Dargani, et al.
Bipolar Disorders|November 27, 2008
Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychoticsChristoph U Correll, Anne M Frederickson, John M Kane, et al.
The Journal of Clinical Psychiatry|May 4, 2006
Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugsChristoph U Correll, Anne M Frederickson, John M Kane, et al.
Schizophrenia Research|October 31, 2006
Does antipsychotic polypharmacy increase the risk for metabolic syndrome?Christoph U Correll, Anne M Frederickson, John M Kane, et al.
American Journal of Therapeutics|April 28, 2022
Pharmacological Management of Primary Arterial Hypertension: A Century of Expert Opinions in Cecil Textbook of MedicinePeter Manu, Liliana M Rogozea, Andreea Ivanescu-Lint, et al.
Journal of Child and Adolescent Psychopharmacology|August 10, 2011
Antipsychotic drug administration does not correlate with prolonged rate-corrected QT interval in children and adolescents: results from a nested case-control studyChristoph U Correll, Jennifer Harris, Vicki Figen, et al.
Pageof 10

Showing results (51-60 of 93) with videos related to

Sort By:
Pageof 10
Expert Review of Clinical Pharmacology|January 19, 2018
The pharmacological management of metabolic syndromeJulie Rask Larsen, Lorena Dima, Christoph U Correll, et al.
Expert Opinion on Drug Metabolism & Toxicology|June 6, 2022
Drug-drug interactions involving antipsychotics and antihypertensivesCatalin Adrian Buzea, Lorena Dima, Christoph U Correll, et al.
American Journal of Therapeutics|September 1, 2021
Pharmacological Management of Peptic Ulcer: A Century of Expert Opinions in Cecil Textbook of MedicinePeter Manu, Liliana M Rogozea, Vlaicu Sandor, et al.
Expert Opinion on Drug Metabolism & Toxicology|November 12, 2022
Drug-drug interactions involving combinations of antipsychotic agents with antidiabetic, lipid-lowering, and weight loss drugsCatalin Adrian Buzea, Peter Manu, Lorena Dima, et al.
American Journal of Therapeutics|September 27, 2012
Acanthosis nigricans during treatment with aripiprazolePeter Manu, Zainab Al-Dhaher, Navin Dargani, et al.
Bipolar Disorders|November 27, 2008
Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychoticsChristoph U Correll, Anne M Frederickson, John M Kane, et al.
The Journal of Clinical Psychiatry|May 4, 2006
Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugsChristoph U Correll, Anne M Frederickson, John M Kane, et al.
Schizophrenia Research|October 31, 2006
Does antipsychotic polypharmacy increase the risk for metabolic syndrome?Christoph U Correll, Anne M Frederickson, John M Kane, et al.
American Journal of Therapeutics|April 28, 2022
Pharmacological Management of Primary Arterial Hypertension: A Century of Expert Opinions in Cecil Textbook of MedicinePeter Manu, Liliana M Rogozea, Andreea Ivanescu-Lint, et al.
Journal of Child and Adolescent Psychopharmacology|August 10, 2011
Antipsychotic drug administration does not correlate with prolonged rate-corrected QT interval in children and adolescents: results from a nested case-control studyChristoph U Correll, Jennifer Harris, Vicki Figen, et al.
Pageof 10